Abstract
Surgery Partners, Inc. will report first-quarter 2026 results on May 5, 2026, Pre-Market; this preview summarizes the latest quarterly performance, consensus expectations, and analyst views alongside management’s implied projections for revenue, margins, profitability, and adjusted EPS.
Market Forecast
For the current quarter, projections point to revenue of 797.89 million US dollars, up 2.68% year over year, an estimated EBIT of 74.05 million US dollars, down 3.35% year over year, and an adjusted EPS of -$0.12, representing a year-over-year change of -325.10%. No explicit company forecast has been indicated for gross profit margin or net margin for the quarter, and consensus is centered on modest top-line growth with a temporary EPS loss driven by mix and expense timing.
The Surgical Facilities business remains the primary driver of results, with volumes and case mix tracking around low-single-digit revenue growth into this quarter. Within Surgical Facilities, the short-stay orthopedics and spine book is positioned as the key growth engine; as a whole, the Surgical Facilities segment accounted for 885.00 million US dollars last quarter, up 2.38% year over year.
Last Quarter Review
In the previous quarter, Surgery Partners, Inc. delivered revenue of 885.00 million US dollars (up 2.38% year over year), a gross profit margin of 23.98%, a GAAP net loss attributable to the parent company of 15.00 million US dollars, a net profit margin of -1.69%, and adjusted EPS of $0.12 (down 72.73% year over year).
A key financial highlight was top-line outperformance versus expectations, with revenue surpassing estimates by 18.53 million US dollars. The main business highlight was that Surgical Facilities represented essentially all of company revenue, contributing 885.00 million US dollars in the quarter, up 2.38% year over year as volumes held up and mix effects moderated margins.
Current Quarter Outlook
Surgical Facilities: Volume resilience with a modest growth cadence
The core Surgical Facilities business enters the quarter with a projection for 2.68% revenue growth to 797.89 million US dollars, consistent with a low-single-digit trajectory. Investors will look closely at case volumes in higher-acuity service lines such as orthopedics, spine, cardiology, and gastroenterology, which influence blended pricing and throughput. Seasonality in early-year periods can weigh on net revenue per case due to deductible resets and a higher share of patient responsibility, which in turn can dampen margin conversion despite stable procedure counts.
Labor efficiency and staffing mix remain central to operating leverage in this model. The balance between employed staff, contract labor, and overtime not only shapes unit costs but also affects scheduling flexibility for high-revenue days. A disciplined approach to labor hours per case and productive hours relative to volume will be a focal point for margin stabilization as volumes normalize after the year’s start. In parallel, supply chain management for implants and physician preference items is a recurring lever; even small gains in vendor compliance or pricing on implants can have a meaningful impact on gross margin given the density of orthopedics and spine procedures.
Payor dynamics are another key determinant of the quarter’s profitability. Commercial payor share and contract escalators help sustain pricing power, while growth in government payor mix can compress yields. With an EBIT estimate of 74.05 million US dollars, down 3.35% year over year, the quarter’s implied profit conversion suggests pressure from payor mix and expense timing, even as revenue expands. Execution on scheduling backlogs and throughput optimization in higher-margin service lines will be the swing factors for upside to EBIT relative to projections.
Orthopedics and spine within Surgical Facilities: Growth engine with mix sensitivity
Within Surgical Facilities, the short-stay orthopedics and spine book remains the most promising source of incremental contribution, supported by ongoing clinical shifts toward outpatient settings and enhanced anesthesia and pain protocols that facilitate same-day discharges. While the company reports Surgical Facilities as a unified revenue stream, last quarter’s 885.00 million US dollars (up 2.38% year over year) captures the combined impact of these service lines and underscores the importance of maintaining case-flow in these categories. The current quarter’s uptick in revenue, even with an expected loss at the EPS line, implies that volume in these procedures continues to expand, but margins are constrained by typical early-year dynamics and cost inputs.
The economic profile of orthopedics and spine is highly sensitive to implant costs and physician preference items. Savings from vendor standardization, implant inventory turns, and improved procurement terms can materially influence gross margin, especially when procedure counts are rising. Case mix within orthopedics also matters—higher complexity mixes can support better revenue per case but may carry elevated supply costs; conversely, more routine cases can enhance throughput and staff productivity. The operating challenge this quarter is to protect unit economics while moving greater volumes across diversified sites and geographies.
Throughput and scheduling efficiency directly affect profitability in these lines. Minimizing turnover time between cases, aligning block schedules with peak physician availability, and improving pre-authorization success rates all increase productive capacity and reduce revenue leakage. Where volume growth has recovered fastest, facilities that maintain high block utilization and low cancellation rates should see better conversion of revenue to EBIT. Those execution areas will be watched closely as investors assess whether the modest revenue growth translates into progressive margin normalization in the second half of the year.
Key stock-price drivers: EPS swing, expense timing, and cash-cost visibility
The most visible risk-reward toggle this quarter is the projected swing to an adjusted EPS loss of -$0.12, set against modest revenue growth of 2.68%. The implied mismatch highlights a period of expense catch-up and mix pressure that could overshadow healthy procedure activity. Investors will evaluate whether the factors depressing EPS are transient—such as early-year deductible dynamics, labor normalization, or the timing of professional fees—or whether they indicate a more persistent drag from payor mix or case mix shifts. Clarity on the cadence of expense normalization will likely drive the stock’s response to in-line top-line results.
Gross margin behavior is central to sentiment, even though explicit guidance for the quarter is not provided. Last quarter’s gross margin of 23.98% provides a marker; investors will parse commentary on procurement initiatives, supply chain reliability, and any incremental savings from vendor agreements. If purchasing discipline shows early traction, the EBIT decline implied by the forecast could prove conservative. Conversely, if implant or supply inflation persists without offsetting volume or pricing gains, margin headwinds may extend beyond the seasonally soft first quarter.
Cash-cost visibility around labor, occupancy, and supply expenses will also be pivotal given the negative net margin posted last quarter (-1.69%) and the GAAP net loss of 15.00 million US dollars. Any update on facility-level productivity, completion of integration initiatives, and leverage of centralized services can reframe expectations for margin catch-up in the mid-year period. With revenue estimated at 797.89 million US dollars and EBIT at 74.05 million US dollars, even incremental improvements in labor efficiency or supply pricing could support upside to operating income and narrow the gap to breakeven on an EPS basis. The stock’s reaction is likely to track management’s commentary on these cost curves as much as the headline revenue print.
Analyst Opinions
The prevailing view in recent sell-side commentary has been bullish. Two major institutions reaffirmed constructive stances following the most recent quarterly update while adjusting near-term price targets to reflect execution timing and expense pressures. RBC maintained an Outperform rating and set a 12-month price target of 20.00 US dollars in early March 2026, emphasizing a favorable multi-quarter trajectory for volume and revenue despite a short-term profit step-down. UBS reiterated a Buy rating and established a 12-month price target of 21.00 US dollars the following day, citing confidence in the company’s ability to convert procedure growth into improved margin as the year progresses.
These bullish views focus on several pillars. First, they frame the expected EPS loss in the current quarter as a function of timing and seasonal dynamics rather than a reset in the underlying demand environment for core procedures. Second, they point to balance-of-year opportunities in mix and procurement to stabilize gross margin from the 23.98% level posted last quarter, with incremental relief as labor normalization and throughput initiatives mature. Third, they see the 2.68% projected revenue growth as a reasonable floor, with potential upside if orthopedic and spine throughput outpaces modeled assumptions and commercial payor share remains stable.
Another component of constructive commentary is the translation of low-single-digit top-line growth into expanding EBIT run rates later in the year. Despite a -3.35% year-over-year EBIT outlook for the current quarter, bullish analysts argue that early-year costs and payor mix distort profitability optics and may not reflect the trajectory into the second and third quarters. They highlight management’s operational levers—scheduling discipline, labor hours optimization, and implant cost management—as the critical variables to restore conversion, noting that even modest gains in these areas can meaningfully affect earnings power given the company’s volume base.
Finally, the bullish camp assesses valuation in the context of execution milestones in the next two quarters. The expectation is that confirmation of sustained case growth, improving procurement metrics, and a clear glide path from negative EPS to positive adjusted earnings will be catalysts for rerating. While targets have been recalibrated to 20.00–21.00 US dollars to reflect near-term expense pressure, the thesis assumes that demand trends in higher-acuity, short-stay settings support gradual margin recovery and a return to profitable growth on an adjusted basis, aligning with the implied revenue growth and operational cadence outlined for the current quarter.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments